Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-96.0%
0%
-96.0%
6 Months
-99.93%
0%
-99.93%
1 Year
-99.92%
0%
-99.92%
2 Years
-99.89%
0%
-99.89%
3 Years
-100.0%
0%
-100.0%
4 Years
-100.0%
0%
-100.0%
5 Years
-100.0%
0%
-100.0%
VBI Vaccines, Inc. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
21.60%
EBIT Growth (5y)
4.34%
EBIT to Interest (avg)
-14.36
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-6.76
Sales to Capital Employed (avg)
0.05
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
13.73%
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
Industry P/E
Price to Book Value
-0.00
EV to EBIT
-0.78
EV to EBITDA
-0.82
EV to Capital Employed
1.17
EV to Sales
3.93
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-150.91%
ROE (Latest)
Negative BV
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Mildly Bullish
RSI
No Signal
Bollinger Bands
Sideways
Mildly Bearish
Moving Averages
Mildly Bearish (Daily)
KST
Mildly Bullish
Bearish
Dow Theory
No Trend
No Trend
OBV
No Trend
No Trend
Shareholding Snapshot : Mar 2024
Shareholding Compare (%holding) 
Majority shareholders
Domestic Funds
Domestic Funds
Held in 24 Schemes (3.78%)
Foreign Institutions
Held by 47 Foreign Institutions (0.52%)
Strategic Entities with highest holding
Highest Public shareholder
Quarterly Results Snapshot (Consolidated) - Mar'24 - QoQ
Mar'24
Dec'23
Change(%)
Net Sales
1.20
0.90
33.33%
Operating Profit (PBDIT) excl Other Income
-11.30
-11.90
5.04%
Interest
2.00
2.10
-4.76%
Exceptional Items
0.00
-1.00
100.00%
Consolidate Net Profit
-17.90
-0.00
Operating Profit Margin (Excl OI)
-9,680.40%
-14,494.70%
481.43%
USD in Million.
Net Sales
QoQ Growth in quarter ended Mar 2024 is 33.33% vs -86.36% in Dec 2023
Consolidated Net Profit
QoQ Growth in quarter ended Mar 2024 is 0.00% vs 100.00% in Dec 2023
Annual Results Snapshot (Consolidated) - Dec'23
Dec'23
Dec'22
Change(%)
Net Sales
8.70
1.10
690.91%
Operating Profit (PBDIT) excl Other Income
-53.30
-79.80
33.21%
Interest
8.10
5.20
55.77%
Exceptional Items
-24.60
-0.20
-12,200.00%
Consolidate Net Profit
-92.80
-113.30
18.09%
Operating Profit Margin (Excl OI)
-6,370.80%
-75,619.20%
6,924.84%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2023 is 690.91% vs 83.33% in Dec 2022
Consolidated Net Profit
YoY Growth in year ended Dec 2023 is 18.09% vs -62.32% in Dec 2022
About VBI Vaccines, Inc. 
VBI Vaccines, Inc.
Biotechnology
VBI Vaccines Inc. is a development-stage biotechnology company. The Company's principal products include cytomegalovirus (CMV) Vaccine Candidate, enveloped Virus Like Particle (eVLP) Vaccine Platform and Lipid Particle Vaccine (LPV) Vaccine Platform. The Company is also engaged in the research and development (R and D) activity. The Company's subsidiaries includes Variation Biotechnologies (US), Inc. (VBI US) and Variation Biotechnologies Inc. (VBI Cda).
Company Coordinates 
Company Details
222 3rd St Ste 2241 , CAMBRIDGE MA : 02142-1259
Registrar Details






